- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03720912
Behavioral Family Therapy and Type One Diabetes
October 18, 2023 updated by: University of California, Davis
Effect of Behavioral Family Therapy on Glycemic Control in Children With Type One Diabetes
Behavioral family therapy, specifically focused on insuring support for the primary caregiver of a child with type one diabetes mellitus and healthy family dynamics, may improve the child's glycemic control as measured by hemoglobin A1c level (HbA1c).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The success or failure of type 1 diabetes mellitus (T1D) management in children depends not only on access to care, diabetes technologies and diabetes education, but also on the abilities of the patient and his/her family to carry out complex demands.
Recent data show that family dynamics play a critical role in determining glycemic control in pediatric patients with T1D.
The investigators prior work (Loomba-Albrecht and Glaser, unpublished data) suggests that the strongest determinants of glycemic control are factors related to the primary caregiver's involvement in supportive relationships with others, either a spouse or other family members.
This provides a potential therapeutic target to improve outcomes for children with T1D.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- University of California-Davis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- age 2 to 17 years
- newly diagnosed (within the past 12 weeks) with T1D
- seeking care at UC Davis
Exclusion Criteria:
- Families will be excluded if the child has severe underlying psychiatric, behavioral or medical conditions which could independently affect parental marital stress
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Online Family Education Modules
Patients will receive online family education modules.
|
The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
|
No Intervention: Control
Patients will not receive any intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c Level
Time Frame: 6, 12, 18, and 24 months
|
The main outcome variable will be the change in glycemic control measured as the mean HbA1c level over the two years following study enrollment.
|
6, 12, 18, and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavioral Affect Rating
Time Frame: At enrollment and approximately 3 months after enrollment
|
22 item assessment of the level of hostility and warmth/supportiveness that each parent has received from his or her partner over the prior month-married parents will complete; Scale range is 1 (always)-7 (never); sclae is divided into two parts, hostility and warmth/support (higher values indicate higher hostility or higher warmth/support)
|
At enrollment and approximately 3 months after enrollment
|
Child Perception of Interparental Conflict (CPIC)
Time Frame: At enrollment and approximately 3 months after enrollment
|
Child's assessment of conflict between parents (completed by children ages 6-18 years of married parents); scale range is 1 (best)-5 (worst), Questions 1 and 4 are reverse scored
|
At enrollment and approximately 3 months after enrollment
|
Family Assessment Device-General Functioning Subscale
Time Frame: At enrollment and approximately 3 months after enrollment
|
Parent reported measure of family environment; Reverse odd questions, Average of all question: 1>x<4; Higher scores indicate more problematic perception of family function.
|
At enrollment and approximately 3 months after enrollment
|
Patient-Reported Outcomes Information System- Short Forms (PROMIS)
Time Frame: At enrollment and approximately 3 months after enrollment
|
A bank of measures that examine aspects of individuals' physical, social, and mental health; Average of questions 1>x<5 (Higher scores indicated more perceived support)
|
At enrollment and approximately 3 months after enrollment
|
FoH-C Frequency of Help
Time Frame: At enrollment and approximately 3 months after enrollment
|
10 item assessment of who provides support in the home for diabetes management tasks; Average of items: 1>x>5; higher scores indicate greater frequency of help
|
At enrollment and approximately 3 months after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 22, 2018
Primary Completion (Actual)
September 1, 2021
Study Completion (Actual)
October 1, 2023
Study Registration Dates
First Submitted
October 22, 2018
First Submitted That Met QC Criteria
October 23, 2018
First Posted (Actual)
October 25, 2018
Study Record Updates
Last Update Posted (Actual)
October 23, 2023
Last Update Submitted That Met QC Criteria
October 18, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1303325
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Online Learning Modules
-
Penn State UniversityNot yet recruiting
-
UConn HealthRecruiting
-
Royal Marsden NHS Foundation TrustRecruitingSolid NeoplasmsUnited Kingdom
-
University of ValenciaCompleted
-
Chinese University of Hong KongRecruitingPsychological Distress | OncologyHong Kong
-
Namik Kemal UniversityCompleted
-
University of North Carolina, Chapel HillCompletedPatient SatisfactionUnited States
-
Milton S. Hershey Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruiting
-
Cairo UniversityCompletedDistance Learning-Online Learning | Traditional Classroom-Based Learning | Coronavirus Disease Social Distancing Measures | Nursing Students' Perception and AchievementEgypt
-
Hospital Israelita Albert EinsteinEmory University; GaiaMais; Instituto Sidarta; Universidade Federal do ABCRecruitingSocial Emotional LearningBrazil